Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
MELBOURNE, Australia, Feb. 23, 2016 -- Gordagen Pharmaceuticals, an Australian nutraceutical and pharmaceutical company, is pleased to announce a collaborative research agreement with Monash University to assess a new drug delivery technology.
The research project will assess the feasibility of using a novel, patent-pending lymph directing drug delivery technology. The technology was developed by researchers at the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology based at the Monash Institute for Pharmaceutical Sciences, Australia's leading Institute in drug delivery and drug discovery. It is anticipated that the technology will help improve the bioavailability of tocotrienols, which forms the basis of Gordagen’s prescription medicines portfolio.
The project, being headed up by Dr. Chris Porter and his team at Monash, will comprise synthesis of tocotrienol derivatives based on the new delivery technology. These molecules will then be tested in validated animal models, initially providing data on the efficiency of absorption and bioavailability.
Following a positive outcome from the program, an exclusive license for the technology as applied to tocotrienols would be negotiated. Minimum commercial terms have already been agreed between the parties.
“We are very excited about this proof of concept project, as it could potentially enable Gordagen to expand its prescription medicines portfolio with a range of New Chemical Entities (NCE’s) protected by a composition of matter patent, which we will have under exclusive license,” said Dr. Ric DeGaris, Chief Operating Officer, Gordagen.
The project is expected to be completed by Q4 2016. It would be anticipated that a resulting license agreement would be finalised shortly afterwards. The program is being supported by a Commonwealth Innovation Grant.
“If the Monash technology improves the bioavailability of tocotrienols, this will strengthen our intellectual property position and add tremendous value to our prescription medicines pipeline. Results will coincide with the launch of our nutraceuticals portfolio in the US this year, making it a period of rapid value building for Gordagen,” said Dr. Glenn Tong, CEO and Managing Director of Gordagen.
Investor and Media Enquiries: Company: Dr Glenn Tong Managing Director & CEO Tel: +61 (0) 412 193 350 Australia / Asia: Paris Brooke Bt Novo Pty Ltd Tel: +61 (0) 407 715 574 United States / Europe: David Burke The Ruth Group O: 646.536.7009 C: 917-618-2651
